Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma

DNA sequencing revealed that mutations in SETD2 occur in 3% to 12% of clear-cell renal cell carcinoma (ccRCC) cases and are associated with poor clinical outcome. In this study, we used an immunohistochemistry (IHC) assay to evaluate the impact of SETD2 loss, with expression of H3K36me3, a nonredund...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Weisi, Fu, Qiang, An, Huimin, Chang, Yuan, Zhang, Weijuan, Zhu, Yu, Xu, Le, Xu, Jiejie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
7300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912287/
https://www.ncbi.nlm.nih.gov/pubmed/26559293
http://dx.doi.org/10.1097/MD.0000000000002004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912287/
https://www.ncbi.nlm.nih.gov/pubmed/26559293
http://dx.doi.org/10.1097/MD.0000000000002004

Ejemplares similares